Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
After finishing at $2.18 in the prior trading day, ATAI Life Sciences N.V (NASDAQ: ATAI) closed at $2.11, down -3.21%. In other words, the price has decreased by -$3.21 from its previous closing price. On the day, 2.28 million shares were traded.
Ratios:
Our goal is to gain a better understanding of ATAI by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.07 and its Current Ratio is at 4.07. In the meantime, Its Debt-to-Equity ratio is 0.19 whereas as Long-Term Debt/Eq ratio is at 0.09.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on November 18, 2024, Reiterated its Buy rating but revised its target price to $10 from $15 previously.
On April 03, 2024, Maxim Group Upgraded its rating to Buy which previously was Hold but kept the price unchanged to $6.
On November 01, 2022, Loop Capital started tracking the stock assigning a Buy rating and target price of $18.Loop Capital initiated its Buy rating on November 01, 2022, with a $18 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 04 ’25 when SAHIL KIRPEKAR bought 80,000 shares for $2.48 per share.
Kirpekar Sahil sold 48,563 shares of ATAI for $65,560 on Mar 21 ’25. The Chief Business Officer now owns 115,636 shares after completing the transaction at $1.35 per share. On Mar 21 ’25, another insider, Craig Kevin James, who serves as the Chief Medical Officer of the company, sold 11,563 shares for $1.35 each. As a result, the insider received 15,610 and left with 8,437 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 1283.61 while its Price-to-Book (P/B) ratio in mrq is 2.77.
Stock Price History:
Over the past 52 weeks, ATAI has reached a high of $2.64, while it has fallen to a 52-week low of $1.03. The 50-Day Moving Average of the stock is 22.43%, while the 200-Day Moving Average is calculated to be 38.60%.
Shares Statistics:
A total of 199.78M shares are outstanding, with a floating share count of 137.08M. Insiders hold about 31.72% of the company’s shares, while institutions hold 9.93% stake in the company.
Earnings Estimates
The current market rating for ATAI Life Sciences N.V (ATAI) reflects the collective analysis of 3.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.1, with high estimates of -$0.07 and low estimates of -$0.13.
Analysts are recommending an EPS of between -$0.33 and -$0.58 for the fiscal current year, implying an average EPS of -$0.44. EPS for the following year is -$0.6, with 4.0 analysts recommending between -$0.26 and -$0.92.
